Premium
Coughing up a Cure for Whooping Cough with Pertussis Toxin
Author(s) -
Tiffany Karen,
Arnholt A.,
Arnholt S.,
Arzumanyan D.,
Arzumanyan L.,
Butt A.,
Houghtaling A.,
Ketelhohn L.,
Levy J.,
Miller N.,
Minerva N.,
Remington E.,
Tiffany B.,
Wankowski J.,
Barbieri Joseph,
Zuverink Madison
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb270
Subject(s) - pertussis toxin , whooping cough , bordetella pertussis , pertactin , g protein , pertussis vaccine , microbiology and biotechnology , receptor , bordetella , medicine , biology , immunology , antigen , vaccination , bacteria , immunization , genetics
The CDC reported 32,971 cases of pertussis, or whooping cough, in 2014. This respiratory infection mainly affects unvaccinated infants and toddlers, and symptoms include paroxysmal coughing with whooping, vomiting, and pulmonary complications which can lead to death. Pertussis toxin (PT), produced by the pathogenic bacteria Bordetella pertussis , causes whooping cough by ADP‐ribosylating the G i protein that inactivates adenylyl cyclase. The inactive ADP‐ribosylated G i protein is unable to interact with G protein‐coupled receptors, leading to an increased intracellular concentration of cAMP. Increased concentrations of cAMP can interfere with normal cell signaling, disrupting specific cellular functions. PT is a critical virulence factor for B. pertussis that also has potential to create human immunity against pertussis. The Cedarburg SMART Team (Students Modeling A Research Topic) modeled PT using 3‐D printing technology to study structure‐function relationships. PT contains a total of six subunits, four individual subunits (S1, S2, S3, and S5) and a pair of identical subunits (S4). The A domain consists of the S1 subunit, the catalytic portion of the toxin. Mutations in Glu129 and His35 can reduce ADP‐ribosyltransferase activity. Mutations in Arg9, Asp11, and Arg13 also reduce catalytic activity. Trp26 interacts with NAD + , an important cofactor. The B domain, responsible for binding to cell receptors, contains the remaining subunits. Effective vaccines contain chemically‐inactivated PT. However, whole cell pertussis vaccine may cause severe side effects, while acellular pertussis vaccine is not as potent. Non‐toxic derivatives of pertussis toxin may be engineered, improving the potency of the acellular vaccine without harmful side effects. Support or Funding Information This work was supported by the National Institutes of of Health Science Education Partnership Award (NIH‐SEPA 1R25OD010505‐01) and the National Institutes of Health Clinical and Translational Science Award (NIH‐CTSA UL1RR031973).